235 related articles for article (PubMed ID: 12421949)
21. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL.
Chen JL; Dunbar PR; Gileadi U; Jäger E; Gnjatic S; Nagata Y; Stockert E; Panicali DL; Chen YT; Knuth A; Old LJ; Cerundolo V
J Immunol; 2000 Jul; 165(2):948-55. PubMed ID: 10878370
[TBL] [Abstract][Full Text] [Related]
22. A new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: implication for molecular anti-melanoma immunotherapy.
Blanchet JS; Valmori D; Dufau I; Ayyoub M; Nguyen C; Guillaume P; Monsarrat B; Cerottini JC; Romero P; Gairin JE
J Immunol; 2001 Nov; 167(10):5852-61. PubMed ID: 11698460
[TBL] [Abstract][Full Text] [Related]
23. HLA anchor optimization of the melan-A-HLA-A2 epitope within a long peptide is required for efficient cross-priming of human tumor-reactive T cells.
Chauvin JM; Larrieu P; Sarrabayrouse G; Prévost-Blondel A; Lengagne R; Desfrançois J; Labarrière N; Jotereau F
J Immunol; 2012 Mar; 188(5):2102-10. PubMed ID: 22291187
[TBL] [Abstract][Full Text] [Related]
24. Differences in phenotype and function between spontaneously occurring melan-A-, tyrosinase- and influenza matrix peptide-specific CTL in HLA-A*0201 melanoma patients.
Maczek C; Berger TG; Schuler-Thurner B; Schultz ES; Hamann A; Dunbar PR; Cerundolo V; Steinkasserer A; Schuler G
Int J Cancer; 2005 Jun; 115(3):450-5. PubMed ID: 15688371
[TBL] [Abstract][Full Text] [Related]
25. Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype.
D'Souza S; Rimoldi D; Líenard D; Lejeune F; Cerottini JC; Romero P
Int J Cancer; 1998 Dec; 78(6):699-706. PubMed ID: 9833762
[TBL] [Abstract][Full Text] [Related]
26. Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35).
Loftus DJ; Squarcina P; Nielsen MB; Geisler C; Castelli C; Odum N; Appella E; Parmiani G; Rivoltini L
Cancer Res; 1998 Jun; 58(11):2433-9. PubMed ID: 9622085
[TBL] [Abstract][Full Text] [Related]
27. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
Maeurer MJ; Chan HW; Karbach J; Salter RD; Knuth A; Lotze MT; Storkus WJ
Eur J Immunol; 1996 Nov; 26(11):2613-23. PubMed ID: 8921947
[TBL] [Abstract][Full Text] [Related]
28. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
[TBL] [Abstract][Full Text] [Related]
29. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.
Bettinotti MP; Kim CJ; Lee KH; Roden M; Cormier JN; Panelli M; Parker KK; Marincola FM
J Immunol; 1998 Jul; 161(2):877-89. PubMed ID: 9670966
[TBL] [Abstract][Full Text] [Related]
30. Combinatorial peptide libraries as an alternative approach to the identification of ligands for tumor-reactive cytolytic T lymphocytes.
Pinilla C; Rubio-Godoy V; Dutoit V; Guillaume P; Simon R; Zhao Y; Houghten RA; Cerottini JC; Romero P; Valmori D
Cancer Res; 2001 Jul; 61(13):5153-60. PubMed ID: 11431354
[TBL] [Abstract][Full Text] [Related]
31. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity.
Yang S; Linette GP; Longerich S; Haluska FG
J Immunol; 2002 Jul; 169(1):531-9. PubMed ID: 12077285
[TBL] [Abstract][Full Text] [Related]
32. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy.
Rivoltini L; Loftus DJ; Barracchini K; Arienti F; Mazzocchi A; Biddison WE; Salgaller ML; Appella E; Parmiani G; Marincola FM
J Immunol; 1996 May; 156(10):3882-91. PubMed ID: 8621927
[TBL] [Abstract][Full Text] [Related]
33. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma.
Ayyoub M; Stevanovic S; Sahin U; Guillaume P; Servis C; Rimoldi D; Valmori D; Romero P; Cerottini JC; Rammensee HG; Pfreundschuh M; Speiser D; Lévy F
J Immunol; 2002 Feb; 168(4):1717-22. PubMed ID: 11823502
[TBL] [Abstract][Full Text] [Related]
34. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.
Romero P; Valmori D; Pittet MJ; Zippelius A; Rimoldi D; Lévy F; Dutoit V; Ayyoub M; Rubio-Godoy V; Michielin O; Guillaume P; Batard P; Luescher IF; Lejeune F; Liénard D; Rufer N; Dietrich PY; Speiser DE; Cerottini JC
Immunol Rev; 2002 Oct; 188():81-96. PubMed ID: 12445283
[TBL] [Abstract][Full Text] [Related]
35. A direct comparison of cytolytic T-lymphocyte responses to Melan-A peptides in vitro: differential immunogenicity of Melan-A27-35 and Melan-A26-35.
Chen Q; Jackson H; Cebon J; Gibbs P; Davis ID; Trapani JA
Melanoma Res; 2000 Feb; 10(1):16-25. PubMed ID: 10711636
[TBL] [Abstract][Full Text] [Related]
36. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E
J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898
[TBL] [Abstract][Full Text] [Related]
37. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
Frost PJ; Butterfield LH; Dissette VB; Economou JS; Bonavida B
J Immunol; 2001 Mar; 166(5):3564-73. PubMed ID: 11207317
[TBL] [Abstract][Full Text] [Related]
38. Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humans.
Dutoit V; Rubio-Godoy V; Pittet MJ; Zippelius A; Dietrich PY; Legal FA; Guillaume P; Romero P; Cerottini JC; Houghten RA; Pinilla C; Valmori D
J Exp Med; 2002 Jul; 196(2):207-16. PubMed ID: 12119345
[TBL] [Abstract][Full Text] [Related]
39. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.
Parkhurst MR; Salgaller ML; Southwood S; Robbins PF; Sette A; Rosenberg SA; Kawakami Y
J Immunol; 1996 Sep; 157(6):2539-48. PubMed ID: 8805655
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen.
Schütz A; Oertli D; Marti WR; Noppen C; Padovan E; Spagnoli GC; Heberer M; Zajac P
Cancer Gene Ther; 2001 Sep; 8(9):655-61. PubMed ID: 11593334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]